1 Start 2 Complete InstructionsPlease complete the Module 7: Chronic Kidney Disease Follow-up Survey and tell us what you learned from this module. Your response is important, and will be used to demonstrate the value of this educational program and to guide development of future CME activities. Thank you for your participation. Please provide your email so we can contact you with promotional information including drawings and prizes for completing this survey. This field is optional. Which of the following is needed to properly classify a person’s stage of CKD? * An EGFR A spot albumin:creatinine verified twice A serum creatinine and urine albumin:creatinine verified twice An eGFR and spot albumin:creatinine verified twice At least 2-3 serum creatinine and albumin: creatinine values A patient with type 2 diabetes, hypertension, eGFR ≥90 mL/min/1.73m2, and albuminuria of >300 mg/g presents for follow-up. Based on current guidelines, how frequently should you monitor kidney function in this patient? * No need for regular monitoring because eGFR is normal Once a year Twice a year Three times a year Four times a year Which of the following cardiovascular risks increases the most as CKD stage increases? * Myocardial infarction Atrial fibrillation Heart failure Stroke All of the above A 67-year-old woman with type 2 diabetes, ischemic cardiomyopathy complicated by HFrEF, with NYHA class II symptoms and CKD. Her medications include aspirin, atorvastatin, and appropriate GDMT. What would you do next to decrease risk of HF events or CKD progression in this patient? * Add an SGLT-2 inhibitor Add a GLP-1 RA Add either an SGLT-2i or GLP-1 RA Unsure According to the 2022 American Diabetes Association (ADA) guidelines, if a patient is unable to use an SGLT-2 inhibitor, which agent is recommended to reduce the risk of CKD progression and CV events in patients with DKD? * GLP-1 RA DPP-4 inhibitor Finerenone Insulin ARNI How many patient encounters have you had in the last 90 days? * <200 200 400 600 800 1000 1200 >1200 As a result of this educational activity, did you make any changes to your clinical practice? * Yes No What specific changes did you make to your practice as a result of information received in this activity? (Select all that apply) * Incorporate albuminuria assessment when evaluating response to CKD therapy or risk of CKD progression. Recommend novel non-steroidal MRAs and SGLT-2is when appropriate for the treatment of CKD. Monitor the response of CKD patients to RAASi therapy, including potential increases in serum creatinine levels or hyperkalemia. Screen or refer at-risk patients for CKD progression accordingly. What additional improvements have you made in your clinical practice after participating in this activity? * What barriers are currently preventing you from making these changes? (select all that apply) * Formulary restrictions Insurance/financial issues Time constraints Lack of interprofessional team support System constraints Treatment related adverse events Patient adherence/compliance None Were the changes that you made in clinical practice beneficial to patient care?* * Yes No Has this course improved the comprehensive treatment of your patients with cardiometabolic disease or cardiometabolic risk? * Yes No Please explain your above answer. * Leave this field blank
